

ICD-10-PCS FY 2021 Update

NOTICE: On December 1, 2020, the Centers for Medicare and Medicaid Services (CMS) posted an addendum to the FY 2021 International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) that is effective January 1, 2021. The specific changes have been outlined below.

New ICD-10-PCS Codes

XW013H6	Introduction of other new technology monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6
XW013K6	Introduction of leronlimab monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6
XW013S6	Introduction of COVID-19 vaccine dose 1 into subcutaneous tissue, percutaneous approach, new technology group 6
XW013T6	Introduction of COVID-19 vaccine dose 2 into subcutaneous tissue, percutaneous approach, new technology group 6
XW013U6	Introduction of COVID-19 vaccine into subcutaneous tissue, percutaneous approach, new technology group 6
XW023S6	Introduction of COVID-19 vaccine dose 1 into muscle, percutaneous approach, new technology group 6
XW023T6	Introduction of COVID-19 vaccine dose 2 into muscle, percutaneous approach, new technology group 6
XW023U6	Introduction of COVID-19 vaccine into muscle, percutaneous approach, new technology group 6
XW033E6	Introduction of etesevimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
XW033F6	Introduction of bamlanivimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
XW033G6	Introduction of REGN-COV2 monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
XW033H6	Introduction of other new technology monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
XW033L6	Introduction of CD24Fc immunomodulator into peripheral vein, percutaneous approach, new technology group 6
XW043E6	Introduction of etesevimab monoclonal antibody into central vein, percutaneous approach, new technology group 6
XW043F6	Introduction of bamlanivimab monoclonal antibody into central vein, percutaneous approach, new technology group 6
XW043G6	Introduction of REGN-COV2 monoclonal antibody into central vein, percutaneous approach, new technology group 6
XW043H6	Introduction of other new technology monoclonal antibody into central vein, percutaneous approach, new technology group 6
XW043L6	Introduction of CD24Fc immunomodulator into central vein, percutaneous approach, new technology group 6
XW0DXM6	Introduction of baricitinib into mouth and pharynx, external approach, new technology group 6
XW0G7M6	Introduction of baricitinib into upper GI, via natural or artificial opening, new technology group 6
XW0H7M6	Introduction of baricitinib into lower GI, via natural or artificial opening, new technology group 6

ICD-10-PCS Index Changes

B
Bamlanivimab Monoclonal Antibody XW0
Baricitinib XW0

C
CD24Fc Immunomodulator XW0
COVID-19 Vaccine XW0
COVID-19 Vaccine Dose 1 XW0
COVID-19 Vaccine Dose 2 XW0

E
Etesevimab Monoclonal Antibody XW0

L
Leronlimab Monoclonal Antibody XW013K6

N
New Technology
Bamlanivimab Monoclonal Antibody XW0
Baricitinib XW0
CD24Fc Immunomodulator XW0
COVID-19 Vaccine XW0
COVID-19 Vaccine Dose 1 XW0
COVID-19 Vaccine Dose 2 XW0
Etesevimab Monoclonal Antibody XW0
Leronlimab Monoclonal Antibody XW013K6
Other New Technology Monoclonal Antibody XW0
REGN-COV2 Monoclonal Antibody XW0

O
Olumiant® use Baricitinib
Other New Technology Monoclonal Antibody XW0

R
REGN-COV2 Monoclonal Antibody XW0

ICD-10-PCS Substance Key and Substance Definitions Table Changes

Substance Key

Trade Name or Synonym	ICD-10-PCS Value	PCS Section
Olumiant®	Baricitinib (M)	New Technology (X)

Substance Definitions

ICD-10-PCS Value	Trade Name or Synonym	PCS Section
Baricitinib (M)	Includes: Olumiant®	New Technology (X)

ICD-10-PCS Tabular Changes

NOTICE: Table XW0 has been updated to reflect the addition of new codes added to the ICD-10-PCS classification, effective January 1, 2021. These have been demarcated in the table with green font AND italics.

X New Technology
W Anatomical Regions
0 Introduction Definition: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
 Explanation: None

Body Part Character 4	Approach Character 5	Device/Substance/Technology Character 6	Qualifier Character 7
1 Subcutaneous Tissue	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
<i>1 Subcutaneous Tissue</i>	<i>3 Percutaneous</i>	<i>H Other New Technology Monoclonal Antibody</i> <i>K Leronlimab Monoclonal Antibody</i> <i>S COVID-19 Vaccine Dose 1</i> <i>T COVID-19 Vaccine Dose 2</i> <i>U COVID-19 Vaccine</i>	<i>6 New Technology Group 6</i>
1 Subcutaneous Tissue	3 Percutaneous	W Caplacizumab	5 New Technology Group 5
<i>2 Muscle</i>	<i>3 Percutaneous</i>	<i>S COVID-19 Vaccine Dose 1</i> <i>T COVID-19 Vaccine Dose 2</i> <i>U COVID-19 Vaccine</i>	<i>6 New Technology Group 6</i>
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	0 Brexanolone	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	2 Ceftazidime-Avibactam Anti-infective	1 New Technology Group 1
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	2 Nerinitide	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	3 Idarucizumab, Dabigatran Reversal Agent	1 New Technology Group 1
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	3 Durvalumab Antineoplastic	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	4 Isavuconazole Anti-infective 5 Blinatumomab Antineoplastic Immunotherapy	1 New Technology Group 1
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	6 Lefamulin Anti-infective	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated 9 Defibrotide Sodium Anticoagulant	2 New Technology Group 2
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	9 Ceftolozane/Tazobactam Anti-infective	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	A Bezlotoxumab Monoclonal Antibody	3 New Technology Group 3
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	A Cefiderocol Anti-infective	<i>6 New Technology Group 6</i>
3 Peripheral Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
<i>3 Peripheral Vein</i>	<i>3 Percutaneous</i>	B Omadacycline Anti-infective	<i>6 New Technology Group 6</i>

XW0 Continued on next page

X New Technology
W Anatomical Regions
0 Introduction

Definition: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Explanation: None

Body Part Character 4	Approach Character 5	Device/Substance/Technology Character 6	Qualifier Character 7
3 Peripheral Vein	3 Percutaneous	C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy	3 New Technology Group 3
3 Peripheral Vein	3 Percutaneous	C Eculizumab D Atezolizumab Antineoplastic	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
3 Peripheral Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
3 Peripheral Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
4 Central Vein	3 Percutaneous	Ø Brexanolone	6 New Technology Group 6
4 Central Vein	3 Percutaneous	2 Ceftazidime-Avibactam Anti-infective	1 New Technology Group 1
4 Central Vein	3 Percutaneous	2 Neritide	6 New Technology Group 6
4 Central Vein	3 Percutaneous	3 Idarucizumab, Dabigatran Reversal Agent	1 New Technology Group 1
4 Central Vein	3 Percutaneous	3 Durvalumab Antineoplastic	6 New Technology Group 6
4 Central Vein	3 Percutaneous	4 Isavuconazole Anti-infective 5 Blinatumomab Antineoplastic Immunotherapy	1 New Technology Group 1
4 Central Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated 9 Defibrotide Sodium Anticoagulant	2 New Technology Group 2
4 Central Vein	3 Percutaneous	9 Ceftolozane/Tazobacatam Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	A Bezlotoxumab Monoclonal Antibody	3 New Technology Group 3
4 Central Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
4 Central Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6

DRG Non-OR XW033C3

X New Technology
W Anatomical Regions
Ø Introduction

Definition: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Explanation: None

XWØ Continued

Body Part Character 4	Approach Character 5	Device/Substance/Technology Character 6	Qualifier Character 7
4 Central Vein	3 Percutaneous	C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy	3 New Technology Group 3
4 Central Vein	3 Percutaneous	C Eculizumab D Atezolizumab Antineoplastic	6 New Technology Group 6
4 Central Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
4 Central Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
4 Central Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
4 Central Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
4 Central Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
4 Central Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
4 Central Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
4 Central Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
4 Central Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
4 Central Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
4 Central Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
4 Central Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
9 Nose	7 Via Natural or Artificial Opening	M Esketamine Hydrochloride	5 New Technology Group 5
D Mouth and Pharynx	X External	6 Lefamulin Anti-infective	6 New Technology Group 6
D Mouth and Pharynx	X External	8 Uridine Triacetate	2 New Technology Group 2
D Mouth and Pharynx	X External	F Other New Technology Therapeutic Substance J Apalutamide Antineoplastic L Erdafitinib Antineoplastic	5 New Technology Group 5
D Mouth and Pharynx	X External	M Baricitinib	6 New Technology Group 6
D Mouth and Pharynx	X External	R Venetoclax Antineoplastic T Ruxolitinib V Gilteritinib Antineoplastic	5 New Technology Group 5
G Upper GI H Lower GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
G Upper GI H Lower GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
Q Cranial Cavity and Brain	3 Percutaneous	1 Eladocogene exuparvovec	6 New Technology Group 6

DRG Non-OR XWØ43C3